Constant Current Versus Constant Voltage Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorXuanwu Hospital, Beijing

About this trial

To compare the efficacy, programming burden, power consumption, and physicians' and patients' satisfaction between current mode and voltage mode of deep brain stimulation in each period one year after surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with idiopathic Parkinson's disease

Aged 18 to 75, no limited sex

After bilateral STN-DBS, yet not powered on

Disqualifiers

Mental disorders or dementia

Pregnant, lactating women or women who are unable to take effective measures to prevent pregnancy

Serious health conditions, such as tumors, liver or kidney diseases, etc.

Epilepsy or other seizure disorders

Trial design

Design model

Parallel

Treatments tested in this trial

  • Constant current (CC) subthalamic nucleus deep brain stimulation

    Other intervention

    For subjects who have decided to undergo STN-DBS surgery and meet the inclusion criteria, the constant current (CC) mode is selected as the original electronic modality one week after surgery. Regardless of any changes in programming parameters over the following year, the constant current (CC) mode will be maintained.

  • Constant voltage (CV) subthalamic nucleus deep brain stimulation

    Other intervention

    For subjects who have decided to undergo STN-DBS surgery and meet the inclusion criteria, the constant voltage (CV) mode is selected as the original electronic modality one week after surgery. Regardless of any changes in programming parameters over the following year, the constant voltage (CV) mode will be maintained.

Treatment groups

180 Participants
are divided into 2 treatment groups
Group A: Constant current (CC) subthalamic nucleus deep brain stimulationExperimental treatment 1 intervention
Group B: Constant voltage (CV) subthalamic nucleus deep brain stimulationActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

The change rate of MDS-UPDRS III

MDS-UPDRS III is the motor examination section of the MDS-UPDRS (Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale), completed by the evaluator, providing an objective assessment of motor symptoms in patients with Parkinson's disease. MDS-UPDRS III ranges from 0-132. The change rate of MDS-UPDRS III in the Stim-On/Med-On state from baseline to 6 months after surgery will be collected. Positive indicates improvement.

Time frame
from baseline to 6 months after surgery

Secondary outcomes

1

MDS-UPDRS I

MDS-UPDRS I is the non-motor experiences of daily living section of the MDS-UPDRS (Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale). Subsection IA is evaluated by the researcher based on all relevant information provided by the patient or their caregiver regarding certain symptoms. Subsection IB is completed by the patient, with assistance from the caregiver if needed, but it must not be completed by the researcher. The change rate of MDS-UPDRS I from baseline to 6 months after surgery will be collected.

Time frame
from baseline to 6 months after surgery
2

MDS-UPDRS II

MDS-UPDRS II is the motor experiences of daily living section of the MDS-UPDRS (Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale) and is a self-reported questionnaire completed by the patient. The change rate of MDS-UPDRS II from baseline to 6 months after surgery will be collected.

Time frame
from baseline to 6 months after surgery
3

MDS-UPDRS IV

MDS-UPDRS IV is the motor complications section of the MDS-UPDRS (Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale). This section is rated by the evaluator, combining information provided by the patient with the evaluator's clinical observation and judgment to generate a comprehensive score. The change rate of MDS-UPDRS IV from baseline to 6 months after surgery will be collected.

Time frame
from baseline to 6 months after surgery
4

Clinical Global Impression (CGI)

The Clinical Global Impression (CGI) is a global assessment scale initially designed by the World Health Organization (WHO) for use in IPSS research to evaluate clinical efficacy. It provides an overall measure of treatment outcomes.

Time frame
from baseline to 6 months after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Xuanwu Hospital, Beijing

Lead sponsor

Beijing Pins Medical Co., Ltd

Collaborator

Chinese PLA General Hospital

Collaborator

Tianjin Huanhu Hospital

Collaborator

Kunming Sanbo Brain Hospital

Collaborator

Xijing Hospital

Collaborator

The First People's Hospital of Changde City

Collaborator

The General Hospital of Southern Theater Command

Collaborator

The First Affilated Hospital of the Medical College, Shihezi University

Collaborator

RenJi Hospital

Collaborator

Changshu Hospital of Traditional Chinese Medicine

Collaborator

Hainan General Hospital

Collaborator

Affiliated Hospital of North Sichuan Medical College

Collaborator

Second Affiliated Hospital of Bengbu Medical College

Collaborator